Practical Management of Adverse Events in Patients Receiving Tarlatamab, a DLL3-targeted Bispecific T-cell Engager Immunotherapy, for Previously Treated Small Cell Lung Cancer DOI Creative Commons
Jacob Sands, Stéphane Champiat, Horst-Dieter Hummel

и другие.

medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown

Опубликована: Окт. 16, 2024

Abstract Tarlatamab is a bispecific T-cell engager (BiTE ® ) immunotherapy targeting delta-like ligand 3 (DLL3) and the cluster of differentiation (CD3) molecule. In phase 2 DeLLphi-301 trial tarlatamab for patients with previously treated small cell lung cancer (SCLC), 10 mg every weeks achieved durable responses encouraging survival outcomes. Analyses updated safety data from showed that most common treatment-emergent adverse events (TEAEs) were cytokine release syndrome (CRS; 53%), pyrexia (38%), decreased appetite (36%), dysgeusia (32%), anemia (30%). CRS was mostly grade 1 or in severity, occurred primarily after first second dose, managed supportive care, which included administration antipyretics (e.g., acetaminophen), intravenous hydration and/or glucocorticoids. Other TEAEs interest neutropenia (16%) immune-effector cell-associated neurotoxicity associated neurologic (10%). Given approved treatment SCLC, raising awareness regarding monitoring management tarlatamab-associated essential. Here, we describe timing, occurrence, duration these AEs review risk mitigation strategies used by clinical investigators during trial.

Язык: Английский

Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial DOI Creative Commons
Joshua Brody,

Judit Jørgensen,

David Belada

и другие.

Blood, Год журнала: 2025, Номер unknown

Опубликована: Янв. 10, 2025

Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) have poor outcomes. Gemcitabine + oxaliplatin (GemOx) rituximab, a standard salvage therapy, yields complete response (CR) rates of approximately 30% and median overall survival (OS) 10-13 months. disease fare worse, CR rate 7% for subsequent therapies OS 6 Epcoritamab, CD3xCD20 bispecific antibody approved the treatment R/R DLBCL after ≥2 therapy lines, has shown promising safety efficacy in various combinations. We report results from phase 1b/2 EPCORE® NHL-2 trial evaluating epcoritamab GemOx patients who were ineligible had failed autologous stem cell transplant (ASCT). received 48-mg subcutaneous 2 step-up doses until progression unacceptable toxicity; was given Q2W 8 doses. The primary endpoint (ORR). As December 15, 2023, 103 enrolled (median follow‑up, 13.2 months). age 72 years challenging-to-treat disease: prior 62%; CAR T, 28%; disease, 52%; to last 70%. ORR/CR 85%/61%. Median duration 23.6 21.6 Common treatment‑emergent adverse events cytopenias cytokine release syndrome (CRS). CRS predictable timing, primarily low grade (52% overall, 1% 3), resolved without leading discontinuation. Epcoritamab yielded deep, durable responses favorable long-term outcomes ASCT‑ineligible DLBCL. NCT04663347

Язык: Английский

Процитировано

1
Practical management of adverse events in patients receiving tarlatamab, a delta‐like ligand 3–targeted bispecific T‐cell engager immunotherapy, for previously treated small cell lung cancer DOI Creative Commons
Jacob Sands, Stéphane Champiat,

H.-D. Hummel

и другие.

Cancer, Год журнала: 2025, Номер 131(3)

Опубликована: Янв. 28, 2025

Tarlatamab is a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 (DLL3) and the cluster of differentiation (CD3) molecule. In phase 2 DeLLphi-301 trial tarlatamab for patients with previously treated small cell lung cancer, 10 mg every weeks achieved durable responses encouraging survival outcomes. Analyses updated safety data from demonstrated that most common treatment-emergent adverse events were cytokine release syndrome (53%), pyrexia (38%), decreased appetite (36%), dysgeusia (32%), an emia (30%). Cytokine was mostly grade 1 or in severity, occurred primarily after first second dose, managed supportive care, which included administration antipyretics (e.g., acetaminophen), intravenous hydration, and/or glucocorticoids. Other effects interest neutropenia (16%) immune effector cell-associated neurotoxicity associated neurologic (10%). Given approved treatment raising awareness regard to monitoring management tarlatamab-associated essential. Here, authors describe timing, occurrence, duration these review risk-mitigation strategies used by clinical investigators during trial.

Язык: Английский

Процитировано

1
Immuno-oncology in the daily practice DOI
Ariane Laparra

Current Opinion in Oncology, Год журнала: 2025, Номер unknown

Опубликована: Янв. 27, 2025

Purpose of review Immune checkpoint inhibitors (ICI) have become an integral part oncology treatment. ICI currently has approval for more than thirty tumor types with proven efficacy. However, can expose patients to inflammatory side effects, such as immuno-related adverse events (irAE). The spectrum irAE and the time onset be very broad, sometimes leading patient's death. Additionally, could associated chronic or long-term that impact quality life. expansion indications immunotherapy in early adjuvant neoadjuvant stages is altering benefit-risk balance these therapies. Furthermore, combination immunotherapies other treatments makes interpretation difficult. To date, no predictive factors been identified routine practice identify at risk developing serious toxicity. Recent findings This led us develop a patient care pathway dedicated management toxicities, enabling detection improve outcomes. Summary We presented novel based on clinical evaluation, encompassing daily hospital devoted iTox multidisciplinary board, pharmacovigilance database. involves translational research program. toxicity day allowed stage event establish whether anticancer treatment was responsible symptoms and/or biological abnormalities. objective this enhance life compliance treatment, while minimizing necessity unscheduled care.

Язык: Английский

Процитировано

0
Adopting tomorrow’s therapies today: a perspective review of adoptive cell therapy in lung cancer DOI Creative Commons
Faith Abodunrin, Daniel J. Olson,

Oluwatosin Emehinola

и другие.

Therapeutic Advances in Medical Oncology, Год журнала: 2025, Номер 17

Опубликована: Янв. 1, 2025

Lung cancer is the leading cause of all cancer-related deaths in United States and remains a global health challenge. While targeted therapy has revolutionized treatment landscape nonsmall cell lung cancer, many patients lack actionable mutations. Immunotherapy, particularly immune checkpoint inhibitors (ICIs), have significantly impacted outcomes last decade. Some patients, however, never respond or become refractory to ICIs. Newer therapies aimed at augmenting system enhancing antitumor effects are currently being explored. Adoptive (ACT) employs T cells isolated from either tumors peripheral blood often engineers them effect response. Chimeric antigen receptor (CAR-T) therapy, engineered tumor-infiltrating lymphocytes examples adoptive cellular therapies. CAR-T been successful hematological malignancies with several CAR products gaining approval cancers. The success ACTs cancers fueled research into role these solid including cancer. Many trials had early promising results, clinical enrolling. There limitations efficacy ACTs, as well risks benefits individual subtypes ACT. With growing knowledge about tumor antigens more advanced engineering, there potential for ACT result durable responses immunologically “cold” tumors. Here, we review major evidence supporting their use challenges, future perspectives ACTs. Additionally, include engagers mRNA vaccine studies combinatorial strategies

Язык: Английский

Процитировано

0
The Role of STEAP1 in Prostate Cancer: Implications for Diagnosis and Therapeutic Strategies DOI Creative Commons
Lingling Zhang,

Xinyi Ren,

Ran An

и другие.

Biomedicines, Год журнала: 2025, Номер 13(4), С. 794 - 794

Опубликована: Март 26, 2025

Prostate cancer (PCa) is one of the most common malignancies and second leading cause cancer-related death in men worldwide. The six-transmembrane epithelial antigen prostate 1 (STEAP1) exceptionally overexpressed PCa, maintaining high expression even castration-resistant (CRPC) stage, making it a promising target for diagnosis treatment. STEAP1-positive extracellular vesicles STEAP1-PET imaging are optimistic approaches non-invasive detection different stages PCa. STEAP1-targeted therapy includes an antibody–drug conjugate (ADC), chimeric receptor T cell (CAR-T), T-cell engager (TCE), vaccines, which demonstrate valuable therapeutic prospects. This review presents structure pathophysiological function STEAP1, synthesizes cutting-edge advances molecular clinical applications, critically analyzes their translational potential to overcome limitations current PCa

Язык: Английский

Процитировано

0
Histological confirmation and radiotherapy facilitate continuation of epcoritamab in a patient with tumor flare reaction DOI

Mai Fujita,

Sho Okamoto,

Kazuki Jinnouchi

и другие.

International Journal of Hematology, Год журнала: 2025, Номер unknown

Опубликована: Март 29, 2025

Язык: Английский

Процитировано

0
Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy DOI Creative Commons
A. C. Chiang,

M.E. Olmedo García,

Jennifer W. Carlisle

и другие.

ESMO Open, Год журнала: 2025, Номер 10(4), С. 104538 - 104538

Опубликована: Апрель 1, 2025

Tarlatamab, a bispecific T-cell engager immunotherapy targeting delta-like ligand 3, has demonstrated promising survival outcomes in small-cell lung cancer (SCLC). Given the risk of cytokine release syndrome (CRS), initial clinical trials incorporated 48-72-h inpatient monitoring cycle 1. Patients with previously treated SCLC were enrolled into DeLLphi-300 part F, which evaluated safety tarlatamab 10 mg every 2 weeks (Q2W) 6-8-h outpatient following 1 doses. The primary endpoint, safety, was compared patients from A receiving Q2W 48-h for In 1, rates treatment-related adverse events and hospitalizations, including emergency room visits, similar between (n = 30) 58) groups (93% versus 100% 27% 34%, respectively). incidence all grade serious CRS during (any grade: 60% 62%; serious: 17% 22%). median time to resolution 3 days both groups. Safety outcomes, hospitalization rates, this first-in-human study administration

Язык: Английский

Процитировано

0
Predicting the future of autoimmune encephalitides DOI
Mar Guasp, Josep Dalmau

Revue Neurologique, Год журнала: 2024, Номер unknown

Опубликована: Сен. 1, 2024

Язык: Английский

Процитировано

1
Practical Management of Adverse Events in Patients Receiving Tarlatamab, a DLL3-targeted Bispecific T-cell Engager Immunotherapy, for Previously Treated Small Cell Lung Cancer DOI Creative Commons
Jacob Sands, Stéphane Champiat, Horst-Dieter Hummel

и другие.

medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown

Опубликована: Окт. 16, 2024

Abstract Tarlatamab is a bispecific T-cell engager (BiTE ® ) immunotherapy targeting delta-like ligand 3 (DLL3) and the cluster of differentiation (CD3) molecule. In phase 2 DeLLphi-301 trial tarlatamab for patients with previously treated small cell lung cancer (SCLC), 10 mg every weeks achieved durable responses encouraging survival outcomes. Analyses updated safety data from showed that most common treatment-emergent adverse events (TEAEs) were cytokine release syndrome (CRS; 53%), pyrexia (38%), decreased appetite (36%), dysgeusia (32%), anemia (30%). CRS was mostly grade 1 or in severity, occurred primarily after first second dose, managed supportive care, which included administration antipyretics (e.g., acetaminophen), intravenous hydration and/or glucocorticoids. Other TEAEs interest neutropenia (16%) immune-effector cell-associated neurotoxicity associated neurologic (10%). Given approved treatment SCLC, raising awareness regarding monitoring management tarlatamab-associated essential. Here, we describe timing, occurrence, duration these AEs review risk mitigation strategies used by clinical investigators during trial.

Язык: Английский

Процитировано

0